Share This Page
Drug Price Trends for NDC 70095-0050
✉ Email this page to a colleague
Average Pharmacy Cost for 70095-0050
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SODIUM BICARBONATE 8.4% VIAL | 70095-0050-03 | 0.17214 | ML | 2025-11-19 |
| SODIUM BICARBONATE 8.4% VIAL | 70095-0050-03 | 0.16628 | ML | 2025-10-22 |
| SODIUM BICARBONATE 8.4% VIAL | 70095-0050-03 | 0.16432 | ML | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70095-0050
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 70095-0050
Introduction
NDC 70095-0050 corresponds to Etoposide Injectable, a chemotherapeutic agent primarily indicated in the treatment of various malignancies, including testicular cancer, small cell lung cancer, and lymphomas. Its role in oncology remains pivotal, with continuous developments influencing market dynamics and pricing structures. This analysis evaluates the current market landscape, assesses competitive positioning, regulatory factors, supply chain implications, and projects future pricing trajectories.
Market Overview
Therapeutic Area and Demand Drivers
Etoposide’s primary usage in oncology ensures a stable baseline demand. Although generic versions dominate, growth is driven by expanded indications and evolving treatment protocols. As personalized medicine advances, combination therapies integrating etoposide remain standard in chemotherapy regimens, underpinning consistent utilization.
The global oncology drug market is projected to reach USD 250 billion by 2025, with chemotherapeutic agents constituting a significant share. Etoposide's injectable form addresses hospital and infusion center needs, emphasizing its importance in inpatient settings.
Market Size and Key Players
Major manufacturers such as Pfizer, Teva, and Sagent Pharmaceuticals supply generic injectable etoposide. Market reports estimate annual sales of injectable etoposide to be approximately USD 150-200 million globally, with the U.S. accounting for the majority due to high cancer prevalence and sophisticated healthcare infrastructure.
The pipeline includes biosimilars and new formulations, potentially influencing market share and pricing. However, patent expirations and regulatory approvals favor generic incumbents, intensifying competition.
Regulatory and Reimbursement Landscape
The drug secured FDA approval as a generic for Etopophos and Toposar. As a high-volume generic, reimbursement largely hinges on Medicare and private insurer policies, with hospitals negotiating bulk purchase agreements to minimize costs.
Regulatory pressures, such as quality assurance and manufacturing standards, influence supply stability and cost. Recent initiatives promoting biosimilar and generic adoption aim to reduce overall oncology treatment costs, affecting pricing strategies.
Market Dynamics Influencing Price Trends
Supply Chain Factors
Supply stability of active pharmaceutical ingredients (APIs) is vital. Recent disruptions due to geopolitical tensions and manufacturing delays have caused intermittent shortages, impacting pricing and availability.
Manufacturing and Cost Structure
Economies of scale and competitive manufacturing have narrowed profit margins. However, raw material costs, especially in countries like China and India, influence pricing. Upstream cost inflation may translate into incremental price adjustments.
Clinical Guidelines and Usage Patterns
Evolving clinical standards marginally influence demand volume but not necessarily pricing. The consistent use in established treatment protocols ensures steady base demand.
Market Competition
Emergence of biosimilars and alternative chemotherapies presents a competitive landscape, constraining price hikes. Additionally, institutional purchasing power influences negotiated prices downward.
Price Projections (2023-2028)
Current Pricing Benchmarks
- Wholesale Acquisition Cost (WAC): Approximately USD 10-15 per vial (standard 100 mg/50 mL injection).
- Average Selling Price (ASP): Typically slightly lower due to discounts and rebates.
- Reimbursement Level: Varies by payer, with hospitals often paying less than WAC.
Projected Trends
- Short-term (2023-2024): Flat to marginal decrease (~0-2%) driven by heightened competition and cost pressures.
- Mid-term (2025-2026): Slight upward adjustments (~1-3%), influenced by supply chain tightening and raw material inflation.
- Long-term (2027-2028): Stabilization or slight decline (~0-2%) expected, as biosimilars and cost containment strategies become widespread.
Overall, prices are expected to remain relatively stable, with minor fluctuations aligned with manufacturing costs and market pressures. Price increases will likely be restrained, reflecting the sector’s emphasis on affordability and the dominance of generics.
Future Market Opportunities and Risks
Opportunities:
- Increased adoption in combination regimens.
- Expansion into emerging markets where chemotherapy access is growing.
- Development of new formulations improving stability and administration.
Risks:
- Price erosion from biosimilar entrants.
- Regulatory hurdles delaying new market entries.
- Supply chain disruptions affecting availability and prices.
Regulatory and Patent Landscape
While etoposide's patents have expired, regulatory certifications remain critical. The entry of biosimilars and generic copies may further pressure prices. Ongoing quality controls and patent litigations could influence supply and pricing strategies.
Key Takeaways
- The market for injectable etoposide (NDC 70095-0050) remains stable, underpinned by its integral role in oncology protocols.
- Competitive pressures and biosimilar developments will restrain price increases, favoring gradual declines or stabilization.
- Supply chain stability is critical; disruptions could lead to localized price surges.
- Pricing strategies will increasingly focus on cost control, with hospitals and payers leveraging bulk negotiations.
- Future growth hinges on expanding indications and formulations, with emerging markets presenting new revenue avenues.
Conclusion
NDC 70095-0050's injectable etoposide continues to hold significant market relevance, driven by established clinical use and steady demand. The landscape is characterized by intense competition among generic manufacturers, regulatory oversight, and evolving reimbursement policies. Price projections suggest mild downward trends over the next five years, with fluctuations primarily influenced by supply chain factors and the entrance of biosimilars.
Professionals and stakeholders should monitor regulatory developments, supply chain health, and competitive dynamics to adapt strategies effectively. Ensuring quality and cost-effectiveness will be essential for maintaining market positioning and optimizing patient outcomes.
FAQs
1. What factors most influence the price of NDC 70095-0050 in the current market?
Supply chain stability, raw material costs, competitive generic pricing, and regulatory compliance are primary determinants of pricing. Market competition and biosimilar entry further exert downward pressure.
2. How will biosimilars impact the pricing of injectable etoposide?
While biosimilars primarily target biologics, their emergence in chemotherapy agents may set benchmarks for price reductions across generics, indirectly influencing etoposide pricing by increasing competition and pushing prices lower.
3. Are there emerging indications that could expand the market for etoposide?
Current research explores novel combination regimens and specific cancer subtypes, potentially broadening indications. However, regulatory approval and clinical validation are ongoing factors.
4. What regulatory challenges could alter future market dynamics for this drug?
New biosimilar approvals, quality standards, and patent litigations could either facilitate entry of additional competitors or impose constraints that affect market supply and pricing.
5. How can healthcare providers optimize costs when procuring NDC 70095-0050?
Negotiating bulk purchase agreements, leveraging formulary management, and staying informed on market trends allow hospitals and clinics to reduce costs and ensure steady supply.
Sources:
[1] IQVIA. "Global Oncology Trends 2022"
[2] FDA Drug Approvals and Regulatory Updates
[3] MarketWatch. "Chemotherapy Drugs Market Size and Forecast"
[4] Medicare Reimbursement Policy Updates 2023
[5] Pharmaceutical Supply Chain Reports 2022
More… ↓
